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Abstract: Simple, convenient, and reliable preoperative prognostic indicators are needed to estimate
the future risk of recurrences and guide the treatment decisions associated with breast cancer. We
evaluated preoperative hematological markers related to recurrence and mortality and investigated
independent risk factors for recurrence and mortality in patients after breast cancer surgery. We
reviewed electronic medical records of patients with invasive breast cancer diagnosed at our tertiary
institution between November 2005 and December 2010 and followed them until 2015. We compared
two groups of patients classified according to recurrence or death and identified risk factors for
postoperative outcomes. Data from 1783 patients were analyzed ultimately. Cancer antigen (CA)
15-3 and red cell distribution width (RDW) had the highest area under the curve values among
several preoperative hematological markers for disease-free survival and overall survival (0.590
and 0.637, respectively). Patients with both preoperative CA 15-3 levels over 11.4 and RDW over
13.5 had a 1.7-fold higher risk of recurrence (hazard ratio (HR): 1.655; 95% confidence interval (CI):
1.154–2.374; p = 0.007) and mortality (HR: 1.723; 95% CI: 1.098–2.704; p = 0.019). In conclusion,
relatively high preoperative RDW (>13.5) and CA 15-3 levels (>11.4) had the highest predictive power
for mortality and recurrence, respectively. When RDW and CA 15-3 exceeded the cut-off value, the
risk of recurrence and death also increased approximately 1.7 times.
Keywords: breast cancer; cancer antigen 15-3; death; recurrence; red cell distribution width
1. Introduction
Breast cancer accounts for approximately 1 in 3 cancers [1,2] and is now regarded
as the most common cancer globally; its incidence increased from 1.7 million in 2005
to 2.4 million cases in 2015 [3]. Above all, breast cancer is currently the main cause of
cancer-related mortality in women [3]. Mercifully, overall breast cancer-related death
rates decreased by 36% from 1989 to 2012 due to enhancements in early detection and
systemic treatments [4,5]. However, nearly 20% of breast cancer patients are diagnosed
at advanced stages and experience recurrence or distant metastasis within 5 years [6].
Both ipsilateral breast tumor recurrence and other locoregional recurrence are associated
with significantly increased risk of distant disease and death [7,8]. Hence, for patients
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with breast cancer, outcome assessment is essential because it certainly impacts treatment
decisions and prognosis.
The traditional prognostic factors for breast cancer are age, axillary lymph node
status, tumor size, histological features (especially histological grade and lympho-vascular
invasion), and molecular subtype including hormone receptor status and human epidermal
growth factor receptor 2 expression [9–12]. In addition to demographic and basic clinical
information, an increasing number of novel prognostic markers including hematological
markers and perioperative anesthetic information have been explored and identified [13,14].
Recently, incorporation of various genetic and molecular biomarkers was attempted to
develop new prognostic models for breast cancer [15]. However, most markers are not
applied in clinical practice routinely, and their applicability may be limited due to high cost
and the need for specialized expertise and equipment. A quick diagnosis of breast cancer
is based on identification of inexpensive biomarkers [16]. Recently, accumulating evidence
demonstrated that cancer-related systemic inflammation plays a significant role in the
development and progression of several neoplastic diseases including breast cancer [17].
Therefore, there is a need to establish low-cost and simple prognostic indicators for breast
cancer using routine hematological markers in a complete blood count.
We aimed to investigate preoperative hematological predictors for disease-free sur-
vival (DFS) and overall survival (OS) and identify independent risk factors for recurrence
and mortality after breast cancer surgery.
2. Materials and Methods
2.1. Study Design
Our study was approved by the Hospital Research Ethics Committee and Institutional
Review Board of Severance Hospital, Yonsei University Health System (approval number
3-2020-0134). The informed consent was waived in view of the retrospective nature of
this study. We collected clinical data from the electronic medical records of consecutive
patients with curative breast cancer surgery between November 2005 and December 2010.
The follow-up documents were reviewed until December 2015. Patients who underwent
multiple procedures, had incomplete information for anesthesia or surgery, or lacked
preoperative hematological data were excluded.
2.2. Data Collection
Data related to the following patients’ demographic information were collected and re-
viewed: age; body mass index (BMI); presence of comorbidities; values of preoperative rou-
tine hematologic markers within 30 days before surgery, i.e., hemoglobin, hematocrit, red
blood cell (RBC) count, RBC distribution width (RDW), platelet distribution width (PDW),
white blood cell (WBC) count, neutrophil, lymphocyte, neutrophil-to-lymphocyte ratio
(NLR), platelet, mean platelet volume (MPV), prothrombin time (PT), alkaline phosphatase
(ALP), carcinoembryonic antigen (CEA), and cancer antigen (CA) 15-3; and administered
anesthetics and analgesics. Surgical and histopathological information was also collected,
including the conducted surgical procedures and the operating time, tumor receptor ex-
pression status including estrogen receptor (ER), progesterone receptor (PR), and human
epidermal growth factor receptor (HER) 2, tumor-node-metastasis (TNM) stage, type of
tumor, histological type, and any chemotherapy or radiotherapy performed. We used the
American Joint Committee on Cancer 7th edition criteria to identify the TNM stage [18].
Postoperative assessments included medical history, physical examination, and laboratory
and imaging tests to detect any evidence of recurrence. Local metastasis was deemed to
have occurred if there was tumor presence in the ipsilateral breast, regional lymph nodes,
and/or chest wall. Any recurrence at a distant site, including the contralateral axillary or
supraclavicular lymph nodes, was defined as distant metastasis. Recurrence-free survival
(RFS) was calculated from the date of surgery to the date when locoregional or distant
metastasis was first detected. OS was defined as the interval between the date of the first
curative surgery and the date of the last follow-up or death.
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2.3. Statistical Analysis
Patients were categorized into two groups depending on whether they had recur-
rence (or died) or not. These two groups were compared using the independent two-
sample t-test and χ2 test (Fisher’s exact test) for continuous variables and categorical
variables, respectively.
The Contal and O’Quigley method was used to designate the point where the Kaplan–
Meier survival curves of the two groups differed the most with the log-rank test and
survival optimal cut-off values obtained. Sensitivity and specificity were calculated for
each point using Youden Index cut-off values in the receiver operating characteristic (ROC)
curve and area under curve (AUC) where the sum that reached the maximum was assessed.
Additionally, predictive power was calculated using Harrell’s C-index with the bootstrap-
ping method. The closer the C-index value was to 1.0, the greater the predictive power was.
All potential confounders (chosen based on their clinical significance as reported in the liter-
ature) associated with recurrence and mortality after breast cancer surgery, which were age,
BMI, co-morbidity, anesthetic agent, analgesics, transfusion, steroid, surgical data, surgical
procedure, TNM stage, three receptor status, radiotherapy, neoadjuvant chemotherapy,
adjuvant therapy, and histological grade, were analyzed using univariate and multivariate
Cox regression methods. First, we performed univariate analysis to identify potential
risk factors for postoperative recurrence and mortality; variables with p-values < 0.05
were further subjected to multivariate analysis, following which hazard ratio (HR) and
the associated 95% confidence interval (CI) were calculated. Multivariate Cox regression
processes were additively adjusted for several variables that could be confounding factors.
For stepwise multivariate Cox regression analysis, variables including surgical procedure,
TNM stage, estrogen receptor, and histological grade were adjusted.
We also conducted propensity score matching analysis for sensitivity test to assess the
robustness of our findings regarding the relationship between variables and recurrence (or
mortality). After factors including age, BMI, and comorbidities were matched; the greedy
heuristic algorithm was used to identify the optimally matched groups without dropouts.
This aided in excluding cases with differences that exceeded twice the standard deviation
(SD) while matching similar propensity scores. As a result, a 1 to 5 matching score was
chosen because it carried the strongest statistical power.
All statistical analyses were conducted with SAS, version 9.4 (SAS Institute Inc., Cary,
NC, USA), except for Kaplan–Meier curves, which were constructed using the R statistics
(R studio, Boston, MA, USA), version 3.6.2 (www.r-project.org, accessed on 13 June 2020).
3. Results
3.1. Subjects
We collected the data of 2645 patients who underwent surgery after breast cancer
during the study period. Thirty patients who underwent multiple surgeries, 27 with
unclear anesthetic methods, and 805 who lacked laboratory profiles within the 30 days
before the surgery were excluded. Finally, 1783 patients were analyzed. The mean (SD)
follow-up period for our study population was 68.7 (17.2) months. During the study
period, the postoperative recurrence rate was 7.5% and the all-cause mortality rate was
5.7% (Figure 1).




Figure 1. CONSORT Flow Diagram. 
3.2. Comparison of Patients’ Characteristics 
A comparison of the characteristics of patients who had recurrence (n = 134) with 
those who did not have recurrence (n = 1649) is shown in Table 1. There were no significant 
differences regarding the demographic data and anesthetic information. Values of hemo-
globin and CA 15-3 and surgical information including conducted procedure, TNM stag-
ing, estrogen and progesterone receptor status, histological grade, and status of neo/adju-
vant chemotherapy were significantly different between the two groups even after 1 to 5 
propensity score matching.  
A comparison of the characteristics of patients who died (n = 101) and those who 
survived (n = 1682) is shown in Table 2. The groups were comparable in terms of demo-
graphic data and anesthetic information. Hemoglobin, hematocrit, RBC count, RDW, 
MPV, ALP, and CA 15-3 were significantly different between the two groups. Moreover, 
surgical factors including the procedure performed, TNM stage, estrogen and progester-
one receptor status, histological grade, and status of neo/adjuvant chemotherapy were 
also significantly different between the two groups even after 1 to 5 propensity score 
matching. 
  
Figure 1. CONSORT Flow Diagram.
3.2. Comparison of Patients’ Characteristics
A comparison of the characteristics of patients who had recurrence (n = 134) with
those who did not have recurrence (n = 1649) is shown in Table 1. There were no sig-
nificant differences regarding the demographic data and anesthetic information. Values
of hemoglobin and CA 15-3 and su gical inform tion including conducted proced re,
TNM staging, estrogen and progesterone receptor stat s, histological grade, an status
of neo/adjuvant chemotherapy were significantly different between the two groups even
after 1 to 5 propensity score matching.
A comparison of the characteristics of patients who died (n = 101) and those who
survived (n = 1682) is shown in Table 2. The groups were comparable in terms of demo-
graphic data and anesthetic information. Hemoglobin, hematocrit, RBC count, RDW, MPV,
ALP, and CA 15-3 were significantly different between the two groups. Moreover, surgical
factors including the procedure performed, TNM stage, estrogen and progesterone receptor
status, histological grade, and status of eo/adjuvant chemoth rapy were also si nificantly
different between the two groups even afte 1 to 5 p op nsity score matching.
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Table 1. Patient characteristics based on postoperative recurrence.
Before 1 to 5 Propensity Score Matching After 1 to 5 Propensity Score Matching
Parameters Non-Recurrence(n = 1649)
Recurrence




(n = 129) p-Value
Demographic data
Age (yr) 50.1 ± 9.9 49.7 ± 11.2 0.683 48.7 ± 9.49 49.69 ± 10.88 0.333
Body mass index
(kg/m2) 23.3 ± 3.2 23.0 ± 3.0 0.244 23.0 ± 3.1 23.1 ± 3.0 0.851
Comorbidities
Hypertension 321 (19.5) 30 (22.4) 0.413 114 (17.7) 27 (20.9) 0.382
Diabetes mellitus 110 (6.7) 13 (9.7) 0.183 37 (5.7) 12 (9.3) 0.129
Cardiac 43 (2.6) 4 (3.0) 0.777 18 (2.8) 4 (3.1) 0.775
Pulmonary 27 (1.6) 4 (3.0) 0.287 10 (1.5) 0 (0.0) 0.384
Endocrine 79 (4.8) 7 (5.2) 0.822 26 (4.0) 7 (5.4) 0.474
Renal 10 (0.6) 0 (0.0) >0.999 0 (0.0) 0 (0.0) >0.999
Liver 8 (0.5) 1 (0.8) 0.506 3 (0.5) 1 (0.8) 0.519
Neurological 24 (1.5) 2 (1.5) >0.999 9 (1.4) 1 (0.8) >0.999
Others 10 (0.6) 1 (0.8) 0.578 3 (0.5) 1 (0.8) 0.519
Hematologic
markers
Hemoglobin (g/dl) 12.9 ± 1.2 12.6 ± 1.4 0.032 12.8 ± 1.2 12.6 ± 1.5 0.098
Hematocrit (%) 39.0 ± 3.3 38.2 ± 4.2 0.023 38.9 ± 3.2 38.1 ± 4.2 0.070
RBC count
(106/µL) 4.33 ± 0.38 4.23 ± 0.49 0.018 4.33 ± 0.37 4.23 ± 0.50 0.027
RDW (%) 13.16 ± 1.35 13.55 ± 1.80 0.014 13.20 ± 1.37 13.53 ± 1.80 0.051
PDW (fL) 11.12 ± 1.45 10.97 ± 1.50 0.265 11.09 ± 1.44 10.97 ± 1.49 0.358
WBC count
(103/µL) 6.01 ± 1.74 6.00 ± 1.83 0.983 6.12 ± 1.88 6.01 ± 1.85 0.563
Neutrophil (%) 3.67 ± 1.48 3.75 ± 1.50 0.550 3.75 ± 1.57 3.76 ± 1.52 0.982
Lymphocyte (%) 1.86 ± 0.60 1.76 ± 0.65 0.067 1.88 ± 0.61 1.78 ± 0.66 0.082
NLR 2.16 ± 1.20 2.41 ± 1.49 0.065 2.18 ± 1.17 2.40 ± 1.51 0.109
Platelet (103/µL) 258.17 ± 60.17 252.90 ± 72.14 0.413 262.55 ± 63.35 252.12 ± 72.70 0.131
MPV (fL) 9.77 ± 0.86 9.57 ± 1.06 0.039 9.75 ± 0.86 9.57 ± 1.06 0.079
PT (sec) 11.00 ± 0.76 11.05 ± 0.74 0.540 11.04 ± 0.83 11.05 ± 0.74 0.853
ALP (IU/L) 59.97 ± 20.02 63.52 ± 20.29 0.049 59.14 ± 19.26 63.22 ± 19.89 0.030
CEA (ng/mL) 1.74 ± 3.04 1.91 ± 2.88 0.539 1.62 ± 1.77 1.92 ± 2.93 0.253
CA 15-3 (U/mL) 11.97 ± 6.55 13.78 ± 7.66 0.009 11.95 ± 7.07 13.75 ± 7.68 0.010
Anesthetic
information
Anesthetic agent 0.554 0.480
Sevoflurane 1017 (61.7) 76 (56.7) 399 (61.9) 75 (58.1)
TIVA 20 (1.2) 3 (2.2) 7 (1.1) 2 (1.6)
Desflurane 442 (26.8) 38 (28.4) 190 (29.5) 36 (27.9)
Isoflurane 151 (9.2) 14 (10.5) 40 (6.20) 13 (10.08)
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Table 1. Cont.
Before 1 to 5 Propensity Score Matching After 1 to 5 Propensity Score Matching
Parameters Non-Recurrence(n = 1649)
Recurrence




(n = 129) p-Value
Enflurane 19 (1.2) 3 (2.2) 9 (1.40) 3 (2.33)
Analgesic agents
NSAIDs 1486 (90.1) 125(93.3) 0.230 581 (90.1) 120 (93.0) 0.296
Opioids 1023 (62.0) 87(64.9) 0.508 387 (60.0) 86 (66.7) 0.157
Tramadol 625 (37.9) 43(32.1) 0.182 255 (39.5) 43 (33.3) 0.187




BCS 851 (51.6) 33 (24.6) 329 (51.0) 32 (24.8)
Mastectomy 798 (48.4) 101 (75.4) 316 (49.0) 97 (75.2)
Surgical time 207.8 ± 134.5 221.3 ± 121.9 0.263 204.6 ± 125.3 223.3 ± 123.4 0.120
TNM stage <0.001 <0.001
1 849 (51.5) 31 (23.1) 310 (48.1) 29 (22.5)
2 617 (37.4) 49 (36.6) 258 (40.0) 47 (36.4)
3 183 (11.1) 54 (40.3) 77 (11.9) 53 (41.1)
Receptor status
Estrogen 1185 (71.86) 78 (58.2) <0.001 469 (72.7) 75 (58.1) <0.001
Progesterone 1081 (65.55) 72 (53.7) 0.006 429 (66.5) 71 (55.0) 0.013
HER2 455 (27.59) 31 (23.1) 0.265 156 (24.2) 31 (24.0) 0.970
Histological grade <0.001 <0.001
Well 369 (22.4) 14 (10.5) 152 (23.6) 14 (10.9)
Moderate 740 (44.9) 59 (44.0) 289 (44.8) 55 (42.6)
Poorly 369 (22.4) 57 (42.5) 142 (22.0) 56 (43.4)
Other 171 (10.4) 4 (3.0) 62 (9.6) 4 (3.1)
Neoadjuvant
chemotherapy 64 (3.9) 19 (14.2) <0.001 25 (3.9) 18 (14.0) <0.001
Adjuvant
chemotherapy 937 (56.8) 98 (73.1) <0.001 392 (60.8) 96 (74.4) 0.004
Radiotherapy 1062 (64.4) 83 (61.9) 0.568 429 (66.5) 80 (62.0) 0.326
Data are presented as mean (standard deviation) or number (percentage). Propensity score analysis was matched by factors including age,
body mass index, and comorbidities.
Table 2. Patient characteristics based on postoperative mortality.
Before 1 to 5 Propensity Score Matching After 1 to 5 Propensity Score Matching
Parameters Non-Death(n = 1682)
Death




(n = 89) p-Value
Demographic data
Age (yr) 49.9 ± 9.8 52.4 ± 12.7 0.054 50.8 ± 9.8 50.9 ± 11.8 0.333
Body mass index
(kg/m2) 23.3 ± 3.1 22.8 ± 3.1 0.102 22.9 ± 2.9 22.9 ± 3.1 0.851
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Table 2. Cont.
Before 1 to 5 Propensity Score Matching After 1 to 5 Propensity Score Matching
Parameters Non-Death(n = 1682)
Death




(n = 89) p-Value
Comorbidities
Hypertension 323 (19.2) 28 (27.7) 0.037 110 (24.7) 21 (23.6) 0.382
Diabetes mellitus 110 (6.5) 13 (12.9) 0.015 44 (9.9) 8 (9.0) 0.129
Cardiac 41 (2.4) 6 (5.9) 0.046 4 (0.9) 3 (3.4) 0.775
Pulmonary 25 (1.5) 6 (5.9) 0.007 1 (0.2) 0 (0.0) 0.384
Endocrine 81 (4.8) 5 (5.0) 0.814 17 (3.8) 4 (4.5) 0.765
Renal 9 (0.54) 1 (1.0) 0.443 3 (0.7) 1 (1.1) 0.519
Liver 7 (0.4) 2 (2.0) 0.088 0 (0.0) 0 (0.0) >0.999
Neurological 24 (1.4) 2 (2.0) 0.656 8 (1.8) 2 (2.3) 0.676
Others 11 (0.7) 0 (0.0) >0.999 0 (0.0) 0 (0.0) >0.999
Hematologic
markers
Hemoglobin (g/dl) 12.9 ± 1.2 12.6 ± 1.5 0.069 12.9 ± 1.2 12.5 ± 1.6 0.033
Hematocrit (%) 39.0 ± 3.3 38.1 ± 4.5 0.043 39.0 ± 3.2 37.8 ± 4.6 0.018
RBC count
(106/µL) 4.33 ± 0.38 4.19 ± 0.52 0.007 4.34 ± 0.36 4.16 ± 0.53 0.004
RDW (%) 13.15 ± 1.33 13.84 ± 2.05 0.002 13.11 ± 1.22 13.87 ± 2.17 0.002
PDW (fL) 11.12 ± 1.45 10.91 ± 1.53 0.161 11.04 ± 1.44 10.85 ± 1.48 0.283
WBC count
(103/µL) 5.98 ± 1.73 6.38 ± 2.01 0.053 6.01 ± 1.57 6.38 ± 2.09 0.122
Neutrophil (%) 3.66 ± 1.47 3.95 ± 1.67 0.060 3.67 ± 1.35 3.98 ± 1.72 0.116
Lymphocyte (%) 1.85 ± 0.59 1.90 ± 0.75 0.559 1.88 ± 0.57 1.88 ± 0.77 0.916
NLR 2.17 ± 1.19 2.44 ± 1.66 0.104 2.14 ± 1.17 2.50 ± 1.73 0.057
Platelet (103/µL) 257.92 ± 59.95 255.32 ± 78.72 0.745 264.28 ± 59.61 257.71 ± 80.41 0.467
MPV (fL) 9.77 ± 0.87 9.42 ± 1.03 0.001 9.73 ± 0.89 9.41 ± 1.03 0.003
PT (sec) 11.01 ± 0.75 11.04 ± 0.78 0.627 10.94 ± 0.78 11.01 ± 0.74 0.407
ALP (IU/L) 59.80 ± 19.81 67.53 ± 22.74 0.002 60.48 ± 18.55 65.62 ± 21.67 0.039
CEA (ng/mL) 1.74 ± 3.09 1.93 ± 1.58 0.284 1.83 ± 4.09 1.78 ± 1.41 0.811
CA 15-3 (U/mL) 11.98 ± 6.53 14.25 ± 8.12 0.007 12.21 ± 6.10 13.98 ± 7.56 0.040
Anesthetic
information
Anesthetic agent 0.107 0.174
Sevoflurane 1037 (61.7) 56 (55.5) 268 (60.2) 50 (56.2)
TIVA 21 (1.3) 2 (2.0) 4 (0.9) 1 (1.1)
Desflurane 451 (26.8) 29 (28.7) 128 (28.8) 26 (29.2)
Isoflurane 155 (9.2) 10 (9.9) 41 (9.2) 8 (9.0)
Enflurane 18 (1.1) 4 (4.0) 4 (0.9) 4 (4.5)
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Table 2. Cont.
Before 1 to 5 Propensity Score Matching After 1 to 5 Propensity Score Matching
Parameters Non-Death(n = 1682)
Death




(n = 89) p-Value
Analgesic agents
NSAIDs 1520 (90.4) 91 (90.1) 0.929 404 (90.8) 83 (93.3) 0.453
Opioids 1044 (62.1) 66 (65.4) 0.510 265 (59.6) 59 (66.3) 0.235
Tramadol 643 (38.2) 25 (24.8) 0.007 179 (40.2) 25 (28.1) 0.032




BCS 865 (51.4) 19 (18.8) 218 (49.0) 18 (20.2)
Mastectomy 817 (48.6) 82 (81.2) 227 (51.0) 71 (79.8)
Surgical time 209.5 ± 135.7 197.7 ± 91.5 0.224 204.6 ± 125.3 223.3 ± 123.4 0.120
TNM stage <0.001 <0.001
1 862 (51.3) 18 (17.8) 226 (50.8) 14 (15.7)
2 625 (37.2) 41 (40.6) 166 (37.3) 37 (41.6)
3 195 (11.6) 42 (41.6) 53 (11.9) 38 (42.7)
Receptor status
Estrogen 1215 (72.2) 48 (47.5) <0.001 336 (75.5) 40 (44.9) <0.001
Progesterone 1110 (66.0) 43 (42.6) <0.001 292 (65.6) 38 (42.7) <0.001
HER2 458 (27.2) 28 (27.7) 0.914 123 (27.6) 25 (28.1) 0.932
Histological grade <0.001 <0.001
Well 373 (22.2) 10 (9.9) 116 (26.1) 7 (7.8)
Moderate 760 (45.2) 39 (38.6) 190 (42.7) 33 (37.1)
Poorly 380 (22.6) 46 (45.5) 92 (20.7) 43 (48.3)
Other 169 (10.1) 6 (5.9) 47 (10.6) 6 (6.7)
Neoadjuvantchemotherapy 63 (3.8) 20 (19.8) <0.001 16 (3.6) 19 (21.4) <0.001
Adjuvantchemotherapy 965 (57.4) 70 (69.3) 0.019 268 (60.2) 65 (73.0) 0.023
Radiotherapy 1085 (64.5) 60 (59.4) 0.299 273 (61.4) 55 (61.8) 0.937
Data are presented as mean (standard deviation) or number (percentage). Propensity score analysis was matched by factors including age,
body mass index, and comorbidities.
3.3. Predictors for Postoperative Recurrence and Mortality after Breast Cancer Surgery
Figure 2 shows the Kaplan–Meier curve with a survival optimal cut-off value and
ROC curve of CA 15-3, which was the biomarker with the highest predictive power
for postoperative recurrence. When the survival optimal cut-off value of CA15-3 was
11.4 (p value < 0.001), the Harrell’s C-index (AUC) was 0.590. RDW showed the highest
predictive power regarding postoperative mortality, and the survival optimal cut-off value
was 13.5 (p value < 0.001). The Harrell’s C-index of RDW was 0.637 (Figure 3).
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. . Independent Risk Factors for Postoperative Recurrence and Mortality in Breast Cancer
Surgery
Table 3 lists the factors that affected postoperative breast cancer recurrence as revealed
by competing risk analysis. Multivariate Cox regression with 1 to 5 propensity score
matching showed that perioperative CA 15-3 level > 11.4 (HR, 1.665; 95% CI, 1.154–2.374;
p = 0.007), mastectomy (HR, 2.169; 95% CI, 1.419–3.314; p < 0.001) compared with breast-
conserving surgery, TNM stage 3 (HR, 3.481; 95% CI, 2.136–5.672; p < 0.001) compared with
TNM stage 1, neoadjuvant chemotherapy (HR, 1.957; 95% CI, 1.127–3.397; p = 0.045), and
moderate (HR, 2.071; 95% CI, 1.139–3.766; p = 0.017) or poor histological grade (HR, 3.878;
95% CI, 2.044–7.357; p < 0.001) compared with good histological grade increased the risks
for cancer recurrence.
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Table 3. Independent risk factors for patients with breast cancer associated with postoperative recurrence after Cox
regression analysis with 1 to 5 propensity score matching.
Parameter
Univariate Analysis Multivariate Analysis
HR (95% CI) p-Value HR (95% CI) p-Value
Hematologic markers
RDW (%) >13.4 1.713 (1.196–2.453) 0.004 1.238 (0.849–1.806) 0.267
ALP (IU/L) >63 1.475 (1.040–2.093) 0.030 –
CEA (ng/mL) >2.73 1.653 (1.060–2.577) 0.027 1.543 (0.988–2.411) 0.056
CA 15-3 (U/mL) >11.4 2.145 (1.513–3.040) <0.001 1.655 (1.154–2.374) 0.007
Surgical procedure BCS 1 (ref) 1 (ref)
Mastectomy 2.741 (1.837–4.088) <0.001 2.169 (1.419–3.314) <0.001
TNM stage
1 1 (ref) 1 (ref)
2 1.781 (1.121–2.831) 0.015 1.173 (0.728–1.891) 0.512
3 5.863 (3.725–9.226) <0.001 3.481 (2.136–5.672) <0.001
Estrogen receptor Negative 1 (ref) 1 (ref)
Positive 0.512 (0.360–0.727) <0.001 0.671 (0.455–0.990) 0.045
Progesterone receptor Negative 1 (ref) 1 (ref)
Positive 0.598 (0.422–0.846) 0.004 –
Neoadjuvant chemotherapy 3.090 (1.876–5.089) <0.001 1.957 (1.127–3.397) 0.018
Adjuvant chemotherapy 1.659 (1.116–2.465) 0.013 –
Histological grade
Good 1 (ref) 1 (ref)
Moderate 2.152 (1.194–3.876) 0.011 2.071 (1.139–3.766) 0.017
Poor 4.165 (2.312–7.503) <0.001 3.878 (2.044–7.357) <0.001
Other 0.734 (0.242–2.231) 0.586 0.598 (0.194–1.840) 0.370
Propensity score analysis was matched by factors including age, body mass index, and comorbidities.
The factors associated with postoperative mortality after breast cancer surgery are
presented in Table 4. Multivariate Cox regression analysis with 1 to 5 propensity score
matching showed that RDW > 13.5 (HR, 1.723; 95% CI, 1.098–2.704; p = 0.019), NLR > 2.82
(HR, 1.771; 95% CI, 1.108–2.832; p = 0.017), ALP > 76 (HR, 2.257; 95% CI, 1.412–3.607;
p < 0.001), CEA > 1.57 (HR, 1.553; 95% CI, 1.007–2.395; p = 0.047), mastectomy (HR, 2.993;
95% CI, 1.750–5.118; p < 0.001) compared with breast-conserving surgery, TNM stage 2
(HR, 2.310; 95% CI, 1.239–4.306; p = 0.009) and 3 (HR, 6.563; 95% CI, 3.482–12.370; p < 0.001)
compared with TNM stage 1, neoadjuvant chemotherapy (HR, 1.442; 95% CI, 1.048–3.409;
p = 0.035), and moderate (HR, 3.253; 95% CI, 1.412–7.491; p = 0.006) and poor histological
grade (HR, 6.455; 95% CI, 2.757–15.113; p < 0.001) compared with good histological grade
remained significant factors for an increased risk of postoperative mortality.
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Table 4. Independent risk factors for patients with breast cancer associated with postoperative mortality after Cox regression
analysis with 1 to 5 propensity score matching.
Parameter
Univariate Analysis Multivariate Analysis
HR (95% CI) p-Value HR (95% CI) p-Value
Age
<40 1 (ref) 1 (ref)
40–50 0.528 (0.284–0.980) 0.043 –
50–60 0.622 (0.330–1.170) 0.141 –
60–70 0.701 (0.354–1.389) 0.309 –
≥70 1.343 (0.491–3.669) 0.566 –
Hematologic markers
Hemoglobin (g/dl) 0.809 (0.697–0.940) 0.006 –
RDW (%) >13.5 2.368 (1.546–3.625) <0.001 1.723 (1.098–2.704) 0.019
WBC count (103/µL) 1.137 (1.009–1.281) 0.035 –
NLR >2.82 1.936 (1.238–3.029) 0.004 1.771 (1.108–2.832) 0.017
MPV (fL) >8.6 0.358 (0.213–0.601) <0.001 0.469 (0.271–0.811) 0.007
ALP (IU/L) >76 1.729 (1.104–2.708) 0.017 2.257 (1.412–3.607) <0.001
CEA (ng/mL) >1.57 1.590 (1.046–2.417) 0.031 1.553 (1.007–2.395) 0.047
CA 15-3 (U/mL) >11.5 2.126 (1.396–3.236) <0.001 1.423 (0.919–2.206) 0.115
Surgical procedure BCS 1 (ref) 1 (ref)
Mastectomy 3.287 (1.959–5.516) <0.001 2.993 (1.750–5.118) <0.001
TNM stage
1 1 (ref) 1 (ref)




Estrogen receptor Negative 1 (ref) 1 (ref)
Positive 0.279 (0.184–0.425) <0.001 0.350 (0.219–0.561) <0.001
Progesterone receptor Negative 1 (ref) 1 (ref)
Positive 0.387 (0.254–0.589) <0.001 –
Radiotherapy 1.027 (0.669–1.576) 0.904 –
Neoadjuvant chemotherapy 4.403 (2.649–7.319) <0.001 1.890 (1.048–3.409) 0.035
Adjuvant chemotherapy 1.533(0.959–2.450) 0.074 –
Histological grade
Good 1 (ref) 1 (ref)




Other 2.012 (0.676–5.991) 0.209 1.452 (0.480–4.393) 0.509
Propensity score analysis was matched by factors including age, body mass index, and comorbidities.
4. Discussion
In our study, factors including preoperative routine hematologic markers affecting the
prognosis after breast cancer surgery were investigated through follow-up for over 5 years.
Compared with previous studies related to the outcomes of oncologic patients using blood
tests, our study calculated the survival optimal cut-off value and HR of hematological
markers as well as the predictive power of long-term recurrence and mortality after breast
surgery using a large sample size. Preoperative relatively high RDW (>13.5) had the highest
predictive power for postoperative mortality, and preoperative relatively high CA 15-3
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levels (>11.4) had the highest predictive power for recurrence. When these two factors
exceeded the cut-off value the risk of recurrence and death also increased approximately
1.7 times.
Even though many novel prognostic markers have been explored and identified, the
main problem in most of these studies is that the biomarkers depend on complex molecular
or genetic tests [12,19–22]. In our study, considering that CA 15-3 and RDW are easily
available and inexpensive markers and parameters that are routinely assessed in blood
examination, they could be used as potential novel accurate and reproducible indices to
identify breast cancer patients with poorer outcomes.
Complete blood count is essentially used to assess anemia-related diseases, which usu-
ally have increased risk for surgical mortality and can often be treated before surgery [23,24].
We have used RDW, which describes the size variability of circulating red blood cells, for the
workup of anemia and it has recently been suggested as an inflammatory biomarker [25].
Another mechanism for the association between chronic inflammation and elevated RDW
could be increased red blood cell fragility in inflammatory states secondary to the rise
of lipid oxidation [26]. Additionally, oxidation of hemoglobin from exposure to free rad-
icals [27] signals erythrocyte removal and increases RDW. Other explanations for the
relationship include the increased release and binding of free histones to erythrocytes,
which increases their fragility [28]. Similar to inflammation, the status of oxidative stress
may reduce RBC survival and lead to elevated RDW [29].
Inflammation in the tumor microenvironment promotes tumor growth, invasion,
angiogenesis, and, ultimately, metastasis [30–33]. It is now extensively recognized that
smoldering inflammation plays an important role in the initiation and progression of
cancer [31,33]. In the same manner, Seretis et al. [23] reported RDW to be a useful biomarker
in distinguishing benign and malignant breast tumors. RDW has also recently been
reported as a potential prognostic factor in breast cancer [34,35]. Furthermore, RDW is
considered a biomarker that influences the increased mortality rate in non-cardiac surgery
because anemia, malnutrition, and oxidative stress may be indicated by high RDW [36].
However, our RDW cut-off value (13.5) was relatively low compared to those reported
in other studies (13.75, 13.82, and 13.7). Accordingly, we should pay more attention
and monitor patients that have higher preoperational RDW and try to optimize RDW
before surgery providing interventions such as nutritional support or anti-inflammatory
medications [36]. RDW, which is a potential biomarker of inflammation, might be utilized
to risk-stratify cancer surgical patients and monitor the efficacy of risk-modifying strategies.
Preoperative levels of CA15-3 have an independent association with prognosis in
patients with early-stage breast cancer [37]. It has been shown to be extremely sensitive
for distant metastases, especially those in the bone and liver [38–40]. However, there is
currently no clear clinical cut-off for considering CA15-3 abnormal; cut-offs reported in
other studies have varied from 22 to 60 U/mL [41,42]. The choice of cut-off to classify
CA15-3 could indeed affect the conclusions; a lower cut-off would likely decrease the
predictive value, while a higher cut-off may increase the predictive value [43]. In our study,
CA 15-3 was associated with the risk of recurrence and had predictive power. The cut-off
value was 11.4, and the predicted power was relatively low, with an AUC of 0.59 (negative
predictive value 94.8%, positive predictive value 11.4%). Although it was a cut-off value
in our population, a slight increase in CA 15-3 before surgery may indicate an increased
risk of recurrence. Persistently elevated tumor markers including CA 15-3 are associated
with recurrence or treatment resistance, which may be useful in monitoring treatment
effects [44].
CA 15-3 can be easily and inexpensively tested, but its sensitivity is relatively
low [45,46]. The role of CA 15-3 in breast cancer surveillance remains controversial. More-
over, there is no definite guideline on how often to test; this test alone can increase the
patient’s anxiety enough. Because there were insufficient data including prospective ran-
domized clinical trials to provide evidence on whether detection and treatment of occult or
asymptomatic metastases using CA 15-3 impact on the most significant prognosis, ASCO
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guidelines for follow-up and management of patients with breast cancer [47] have not
recommended the use of CA 15.3 for detecting recurrence routinely. On the contrary,
European Group on Tumor Markers has recommended the use of CA15-3 levels for as-
sessing prognosis, early detection of disease progression, and treatment monitoring in
breast cancer [44]. It was also reported that the preoperative elevation of CA15-3 was asso-
ciated with aggressive characteristics and worse overall survival in breast cancer patients
without distant metastasis [48–50]. Consequently, routine follow-ups of CA 15-3 to check
for relapse after treatment of breast cancer have not yet been not recommended by major
international guidelines [40,47,51] because of its high frequency of false negative and false
positive prediction.
The Nottingham Prognostic Index (NPI), known for prognostic index, is also widely
used for predicting survival in operable primary patients with breast cancer [52,53]. It
is based on tumor size, histologic grade, and lymph node status [54] and is simple and
easy for clinical use. It shows suboptimal performance in predicting tumor recurrence.
The AUCs were 0.66 and 0.63 in the training and test cohorts, respectively [55–58]. In our
findings, RDW had a similar predictive power as that of NPI indicating that information can
be easily obtained through blood tests that can approximately predict a patient’s prognosis.
Biomarkers alone, however, are insufficient to predict the postoperative prognosis in
patients with breast cancer, but correction of RDW before surgery may lower the risk of
postoperative death. Moreover, CA 15-3 is highly related to recurrence, and it can act as a
useful marker for cancer tracing.
Our study has some limitations, including its retrospective cohort design, which
was associated with the selecting bias inclusion of an entire population. Although the
propensity matching score carefully balanced age, sex, and a large host of preoperative
comorbidities that might affect the relationship between RDW and mortality, there still
might be unbalanced preoperative comorbidities or medications explaining the relationship.
These could include differences in the cofactors of hemoglobin production or ischemic
diseases. Therefore, it needs future investigation in a less heterogeneous cohort. Another
limitation is that we did not investigate precise mechanisms including molecular or genetic
explanations regarding how CA 15-3 and RDW act on the oncological outcomes, especially
on breast cancer. In addition, the association scores of multiple variables should be more
clearly identified because CA 15-3 was one of the several significant variables included in
the multivariate Cox regression analysis including propensity matching. Further prospec-
tive studies are needed to determine the role of hematological markers for predictors.
The calculated RDW cut-off value related to the risk of death was 13.5, which was
lower than that reported previously. This shows that even a slight increase in RDW in
breast cancer patients may have a correlation with postoperative mortality. There may
be several reasons for the increase in RDW; therefore, efforts to normalize RDW before
surgery are necessary at least in patients with breast cancer. CA15-3 was associated solely
with the risk of breast cancer recurrence in our study. Although the AUC was relatively
low for predicting recurrence, monitoring of CA 15-3 levels would be somewhat helpful in
the follow-ups for breast cancer recurrence or metastasis.
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